Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVI-HBV-002 in chronic hepatitis B
NCT02693652Phase 2Completed
- Sponsor
- AriBio Lab
- Start
- Oct 2014
- Primary completion
- Aug 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CVI-HBV-002 in Chronic Hepatitis B (CHB) (4 arms), sponsored by AriBio Lab. Primary endpoint: Safety and tolerability. Started Oct 2014; status: completed.
02
Drugs
CVI-HBV-002
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02693652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02693652.